{"entity":{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","aka":["AB122"],"tldr":"Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab.","summary":"Guangzhou Gloria Biosciences' zimberelimab (GLS-010) received NMPA approval in 2021 for relapsed or refractory classical Hodgkin lymphoma after at least two lines of therapy, with a later cervical cancer indication. Outside China, Arcus Biosciences licensed it as AB122 and uses it as the PD-1 backbone with domvanalimab in the STAR-121 and STAR-221 phase 3 trials in lung and gastro-oesophageal cancer. A phase 3 trial in cervical cancer is registered in China.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Zimberelimab","url":"https://clinicaltrials.gov/search?intr=GLS-010"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","cervical"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05798819"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"GLS-010","modality":"Anti-PD-1 monoclonal antibody, intravenous","mechanism":"Blocks PD-1 on T cells so tumour cells cannot switch them off through PD-L1.","approvals":[{"region":"CN","year":2021,"indication":"Relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/zimberelimab/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"trial":[{"id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/"},{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","route":"/trials/nct05798819/"},{"id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/"},{"id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/"},{"id":"nct05909436","kind":"trial","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","route":"/trials/nct05909436/"},{"id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/"},{"id":"nct06727565","kind":"trial","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","route":"/trials/nct06727565/"},{"id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/"},{"id":"nct03547973","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","route":"/trials/nct03547973/"},{"id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/"}]}}